Sartorius Stedim Biotech Aktie
WKN DE: A2AJKS / ISIN: FR0013154002
17.03.2020 19:20:00
|
Sartorius Stedim Biotech Postpones Annual Shareholders' Meeting
AUBAGNE, France, March 17, 2020 /PRNewswire/ -- Sartorius Stedim Biotech S.A. will postpone its Annual General Shareholders' Meeting formerly scheduled for March 24, 2020, to a later date due to the coronavirus pandemic and the associated restrictions imposed on travel and meetings. This was resolved today by the Board of Directors of the company.
As a result of the cancelation of the Annual General Shareholders' Meeting on March 24, 2020, the vote on the resolution on the assignment of the financial result for the year ended December 31, 2019, and the payment of dividends, among other things, will also be deferred.
The 2020 Annual General Shareholders' Meeting is to be scheduled for a new date within six months after the close of the fiscal year ending on December 31, 2019 as provided for under the French Commercial Law. Sartorius Stedim Biotech will inform its shareholders and the public in a timely manner about its further planning.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2019, the company employed approx. 6,200 people, and earned sales revenue of €1,440.6 million according to preliminary figures.
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.
Contact:
Petra Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
www.sartorius.com
View original content:http://www.prnewswire.com/news-releases/sartorius-stedim-biotech-postpones-annual-shareholders-meeting-301025703.html
SOURCE Sartorius Stedim Biotech S.A

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sartorius Stedim Biotechmehr Nachrichten
16.04.25 |
ANALYSE-FLASH: RBC belässt Sartorius Stedim Biotech auf 'Outperform' (dpa-AFX) | |
16.04.25 |
Sartorius Stedim Biotech publishes unaudited first quarter results for 2025 (EQS Group) | |
15.04.25 |
Ausblick: Sartorius Stedim Biotech vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
01.04.25 |
Erste Schätzungen: Sartorius Stedim Biotech stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
25.03.25 |
Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. (EQS Group) | |
17.02.25 |
Sartorius Stedim Biotech releases Universal Registration Document 2024 (EQS Group) | |
07.02.25 |
Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting (EQS Group) | |
28.01.25 |
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024 (EQS Group) |
Analysen zu Sartorius Stedim Biotechmehr Analysen
25.04.25 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
23.04.25 | Sartorius Stedim Biotech Buy | Jefferies & Company Inc. | |
16.04.25 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
16.04.25 | Sartorius Stedim Biotech Market-Perform | Bernstein Research | |
16.04.25 | Sartorius Stedim Biotech Outperform | RBC Capital Markets |
Aktien in diesem Artikel
Sartorius Stedim Biotech | 197,70 | -0,43% |
|